Table 2.

Prevalence ratio (PR) estimates of assisted reproductive technology (ART) use among women diagnosed with breast cancer in California between 2000 and 2015 (n=36,468)

		Full sample (n=36,468)	Received chemotherapy (n=24,908)
Characteristic	Unadjusted PR (95% CI)	Adjusted PR (95% CI)a
Age at diagnosis, years			Unadjusted
18–35	1.00	n/a	1.00
36–45	0.17 (0.13 to 0.22)		0.18 (0.13 to 0.25)
Race and ethnicity			Unadjusted
Non-Hispanic White	1.00		1.00
Non-Hispanic		n/a
Asian/Pacific	0.88 (0.63 to 1.25)		0.67 (0.43 to 1.04)
Islander
Non-Hispanic Black or Hispanic	0.31 (0.21 to 0.46)		0.30 (0.19 to 0.47)
Charlson comorbidity score at diagnosis
0	1.00	1.00	1.00
≥1	0.83 (0.49 to 1.39)	1.04 (0.60 to 1.79)	1.19 (0.63 to 2.25)
Marital status at diagnosis
Single/other	1.00	1.00	1.00
Married	0.68 (0.52 to 0.90)	0.64 (0.47 to 0.86)	0.74 (0.52 to 1.06)
Parity at diagnosis
0 children	1.00	1.00	1.00
≥1 child	0.43 (0.29 to 0.63)	0.39 (0.25 to 0.60)	0.42 (0.26 to 0.68)
Health insurance at diagnosis
Public/other	1.00	1.00	1.00
Private	3.87 (2.11 to 7.11)	2.89 (1.56 to 5.38)	2.06 (1.07 to 3.97)
Census tract–level SES at diagnosis
Low or middle	1.00	1.00	1.00
High	3.59 (2.56 to 5.01)	2.96 (2.07 to 4.25)	3.48 (2.18 to 5.55)
Rurality at diagnosis
Urban	1.00	1.00	1.00
Non-urban	0.16 (0.06 to 0.42)	0.28 (0.10 to 0.75)	0.31 (0.10 to 0.97)

Abbreviations: CI, confidence interval; SES, socioeconomic status.

^aAdjusted models included the following covariates: age at diagnosis, race and ethnicity, Charlson comorbidity score, marital status, parity, health insurance, census tract–level SES, and rurality.